A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies

Alessandra Drusco, Arianna Bottoni, Alessandro Lagana', Mario Acunzo, Matteo Fassan, Luciano Cascione, Anna Antenucci, Prasanthi Kumchala, Caterina Vicentini, Marina P. Gardiman, Hansjuerg Alder, Mariantonia A. Carosi, Mario Ammirati, Stefano Gherardi, Marilena Luscri', Carmine Carapella, Nicola Zanesi, Carlo M. Croce

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Central Nervous System malignancies often require stereotactic biopsy or biopsy for differential diagnosis, and for tumor staging and grading. Furthermore, stereotactic biopsy can be non-diagnostic or underestimate grading. Hence, there is a compelling need of new diagnostic biomarkers to avoid such invasive procedures. Several biological markers have been proposed, but they can only identify specific prognostic subtype of Central Nervous System tumors, and none of them has found a standardized clinical application. The aim of the study was to identify a Cerebro-Spinal Fluid microRNA signature that could differentiate among Central Nervous System malignancies. CSF total RNA of 34 neoplastic and of 14 non-diseased patients was processed by NanoString. Comparison among groups (Normal, Benign, Glioblastoma, Medulloblastoma, Metastasis and Lymphoma) lead to the identification of a microRNA profile that was further confirmed by RT-PCR and in situ hybridization. Hsa-miR-451, -711, 935, -223 and -125b were significantly differentially expressed among the above mentioned groups, allowing us to draw an hypothetical diagnostic chart for Central Nervous System malignancies. This is the first study to employ the NanoString technique for Cerebro-Spinal Fluid microRNA profiling. In this article, we demonstrated that Cerebro-Spinal Fluid microRNA profiling mirrors Central Nervous System physiologic or pathologic conditions. Although more cases need to be tested, we identified a diagnostic Cerebro-Spinal Fluid microRNA signature with good perspectives for future diagnostic clinical applications.

Original languageEnglish
Pages (from-to)20829-20839
Number of pages11
JournalOncotarget
Volume6
Issue number25
Publication statusPublished - 2015

Fingerprint

MicroRNAs
Cerebrospinal Fluid
Central Nervous System
Neoplasms
Biopsy
Biomarkers
Central Nervous System Neoplasms
Medulloblastoma
Neoplasm Grading
Neoplasm Staging
Glioblastoma
In Situ Hybridization
Lymphoma
Differential Diagnosis
RNA
Neoplasm Metastasis
Polymerase Chain Reaction

Keywords

  • Biomarkers
  • Brain tumors
  • Cerebro-spinal f luid (CSF)
  • microRNA

ASJC Scopus subject areas

  • Oncology

Cite this

Drusco, A., Bottoni, A., Lagana', A., Acunzo, M., Fassan, M., Cascione, L., ... Croce, C. M. (2015). A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. Oncotarget, 6(25), 20829-20839.

A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. / Drusco, Alessandra; Bottoni, Arianna; Lagana', Alessandro; Acunzo, Mario; Fassan, Matteo; Cascione, Luciano; Antenucci, Anna; Kumchala, Prasanthi; Vicentini, Caterina; Gardiman, Marina P.; Alder, Hansjuerg; Carosi, Mariantonia A.; Ammirati, Mario; Gherardi, Stefano; Luscri', Marilena; Carapella, Carmine; Zanesi, Nicola; Croce, Carlo M.

In: Oncotarget, Vol. 6, No. 25, 2015, p. 20829-20839.

Research output: Contribution to journalArticle

Drusco, A, Bottoni, A, Lagana', A, Acunzo, M, Fassan, M, Cascione, L, Antenucci, A, Kumchala, P, Vicentini, C, Gardiman, MP, Alder, H, Carosi, MA, Ammirati, M, Gherardi, S, Luscri', M, Carapella, C, Zanesi, N & Croce, CM 2015, 'A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies', Oncotarget, vol. 6, no. 25, pp. 20829-20839.
Drusco A, Bottoni A, Lagana' A, Acunzo M, Fassan M, Cascione L et al. A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. Oncotarget. 2015;6(25):20829-20839.
Drusco, Alessandra ; Bottoni, Arianna ; Lagana', Alessandro ; Acunzo, Mario ; Fassan, Matteo ; Cascione, Luciano ; Antenucci, Anna ; Kumchala, Prasanthi ; Vicentini, Caterina ; Gardiman, Marina P. ; Alder, Hansjuerg ; Carosi, Mariantonia A. ; Ammirati, Mario ; Gherardi, Stefano ; Luscri', Marilena ; Carapella, Carmine ; Zanesi, Nicola ; Croce, Carlo M. / A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. In: Oncotarget. 2015 ; Vol. 6, No. 25. pp. 20829-20839.
@article{4341a667be074da6968e5fe94c923390,
title = "A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies",
abstract = "Central Nervous System malignancies often require stereotactic biopsy or biopsy for differential diagnosis, and for tumor staging and grading. Furthermore, stereotactic biopsy can be non-diagnostic or underestimate grading. Hence, there is a compelling need of new diagnostic biomarkers to avoid such invasive procedures. Several biological markers have been proposed, but they can only identify specific prognostic subtype of Central Nervous System tumors, and none of them has found a standardized clinical application. The aim of the study was to identify a Cerebro-Spinal Fluid microRNA signature that could differentiate among Central Nervous System malignancies. CSF total RNA of 34 neoplastic and of 14 non-diseased patients was processed by NanoString. Comparison among groups (Normal, Benign, Glioblastoma, Medulloblastoma, Metastasis and Lymphoma) lead to the identification of a microRNA profile that was further confirmed by RT-PCR and in situ hybridization. Hsa-miR-451, -711, 935, -223 and -125b were significantly differentially expressed among the above mentioned groups, allowing us to draw an hypothetical diagnostic chart for Central Nervous System malignancies. This is the first study to employ the NanoString technique for Cerebro-Spinal Fluid microRNA profiling. In this article, we demonstrated that Cerebro-Spinal Fluid microRNA profiling mirrors Central Nervous System physiologic or pathologic conditions. Although more cases need to be tested, we identified a diagnostic Cerebro-Spinal Fluid microRNA signature with good perspectives for future diagnostic clinical applications.",
keywords = "Biomarkers, Brain tumors, Cerebro-spinal f luid (CSF), microRNA",
author = "Alessandra Drusco and Arianna Bottoni and Alessandro Lagana' and Mario Acunzo and Matteo Fassan and Luciano Cascione and Anna Antenucci and Prasanthi Kumchala and Caterina Vicentini and Gardiman, {Marina P.} and Hansjuerg Alder and Carosi, {Mariantonia A.} and Mario Ammirati and Stefano Gherardi and Marilena Luscri' and Carmine Carapella and Nicola Zanesi and Croce, {Carlo M.}",
year = "2015",
language = "English",
volume = "6",
pages = "20829--20839",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "25",

}

TY - JOUR

T1 - A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies

AU - Drusco, Alessandra

AU - Bottoni, Arianna

AU - Lagana', Alessandro

AU - Acunzo, Mario

AU - Fassan, Matteo

AU - Cascione, Luciano

AU - Antenucci, Anna

AU - Kumchala, Prasanthi

AU - Vicentini, Caterina

AU - Gardiman, Marina P.

AU - Alder, Hansjuerg

AU - Carosi, Mariantonia A.

AU - Ammirati, Mario

AU - Gherardi, Stefano

AU - Luscri', Marilena

AU - Carapella, Carmine

AU - Zanesi, Nicola

AU - Croce, Carlo M.

PY - 2015

Y1 - 2015

N2 - Central Nervous System malignancies often require stereotactic biopsy or biopsy for differential diagnosis, and for tumor staging and grading. Furthermore, stereotactic biopsy can be non-diagnostic or underestimate grading. Hence, there is a compelling need of new diagnostic biomarkers to avoid such invasive procedures. Several biological markers have been proposed, but they can only identify specific prognostic subtype of Central Nervous System tumors, and none of them has found a standardized clinical application. The aim of the study was to identify a Cerebro-Spinal Fluid microRNA signature that could differentiate among Central Nervous System malignancies. CSF total RNA of 34 neoplastic and of 14 non-diseased patients was processed by NanoString. Comparison among groups (Normal, Benign, Glioblastoma, Medulloblastoma, Metastasis and Lymphoma) lead to the identification of a microRNA profile that was further confirmed by RT-PCR and in situ hybridization. Hsa-miR-451, -711, 935, -223 and -125b were significantly differentially expressed among the above mentioned groups, allowing us to draw an hypothetical diagnostic chart for Central Nervous System malignancies. This is the first study to employ the NanoString technique for Cerebro-Spinal Fluid microRNA profiling. In this article, we demonstrated that Cerebro-Spinal Fluid microRNA profiling mirrors Central Nervous System physiologic or pathologic conditions. Although more cases need to be tested, we identified a diagnostic Cerebro-Spinal Fluid microRNA signature with good perspectives for future diagnostic clinical applications.

AB - Central Nervous System malignancies often require stereotactic biopsy or biopsy for differential diagnosis, and for tumor staging and grading. Furthermore, stereotactic biopsy can be non-diagnostic or underestimate grading. Hence, there is a compelling need of new diagnostic biomarkers to avoid such invasive procedures. Several biological markers have been proposed, but they can only identify specific prognostic subtype of Central Nervous System tumors, and none of them has found a standardized clinical application. The aim of the study was to identify a Cerebro-Spinal Fluid microRNA signature that could differentiate among Central Nervous System malignancies. CSF total RNA of 34 neoplastic and of 14 non-diseased patients was processed by NanoString. Comparison among groups (Normal, Benign, Glioblastoma, Medulloblastoma, Metastasis and Lymphoma) lead to the identification of a microRNA profile that was further confirmed by RT-PCR and in situ hybridization. Hsa-miR-451, -711, 935, -223 and -125b were significantly differentially expressed among the above mentioned groups, allowing us to draw an hypothetical diagnostic chart for Central Nervous System malignancies. This is the first study to employ the NanoString technique for Cerebro-Spinal Fluid microRNA profiling. In this article, we demonstrated that Cerebro-Spinal Fluid microRNA profiling mirrors Central Nervous System physiologic or pathologic conditions. Although more cases need to be tested, we identified a diagnostic Cerebro-Spinal Fluid microRNA signature with good perspectives for future diagnostic clinical applications.

KW - Biomarkers

KW - Brain tumors

KW - Cerebro-spinal f luid (CSF)

KW - microRNA

UR - http://www.scopus.com/inward/record.url?scp=84940730294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940730294&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 20829

EP - 20839

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 25

ER -